EXACTA · UNITED STATES
UAT review checklist
Implementation status against all 30 changes in DM-0003.
Product-content expansion
The US homepage now explains the service, its molecular and functional components, intended clinical role, and patient relevance. Five product pages have been added: What is Exacta?, Technology, Why Exacta?, The process, and News and research updates.
Review the testing-approach comparison, specimen limitations, clinician-report explanation, and workflow. Shared navigation and the original UAT homepage now lead directly to these pages. Commercial superiority, US turnaround, and availability are not asserted without supporting evidence or operational confirmation.
This checklist maps the UAT implementation to DM-0003. Items marked pending depend on approved business, clinical, privacy, or campaign information. UAT is not ready for US ad traffic.
| # | Requirement | Status | What to review / what remains |
|---|---|---|---|
| 1 | US title and H1 | Implemented | US homepage uses the requested title. Original UAT hero and SEO title corrected. |
| 2 | Efficacy claim | Implemented | Study-specific RESILIENT statement replaces the broad homepage efficacy claim; linked evidence summary includes limitations. |
| 3 | Off-label wording | Implemented in US copy | US copy reports biomarkers and drug-response data. Clinical resource pages use server-rendered HCP self-attestation. Old linked PDFs need a separate publication review. |
| 4 | LDT disclaimer | Partial | Footer on every US page. Production clinical report templates need the laboratory team; no clinical reports were altered. |
| 5 | Lab credentials | Pending documents | Laboratory page includes existing Guildford address. Certificate numbers, director, validity, and scope require confirmation. |
| 6 | State availability | Partial | Server-side state check blocks NY, CA, MD, PA, RI, and DC per brief. Other states require verification; no US ordering is activated. |
| 7 | Clinical cases | Pending approval | Homepage case-study promotion replaced by evidence link. Patient consent records, de-identification, typicality disclosures, and case selection require approval. |
| 8 | Exacta-AI | Partial | HTML explanation separates decision support and in-silico evidence from clinical outcomes. Verified training-data and model-validation disclosure pending. |
| 9 | Cost and coverage | Partial | Cost FAQ and payer context added. US price, payment plans, assistance, refund policy, and individual coverage process are missing. |
| 10 | Consent | Partial | US pages run essential-only, with local preference controls and a sensitive-information link. Optional collection remains off. Full consent platform and approved health-data policy pending. |
| 11 | Pixels | Implemented for UAT preview | Disabled cloned tag and analytics injection plugins and the blanket button conversion script. US template loads local assets only; restrictive response policy blocks external scripts, frames, and tracking connections. |
| 12 | HIPAA | Pending organization review | No patient portal was modified. Covered-entity analysis, Notice of Privacy Practices, and vendor agreements require internal/counsel review. |
| 13 | Calls and messaging | Partial | No WhatsApp primary contact on US pages. No callback/SMS collection activated until verified US number, provider, and consent wording are supplied. |
| 14 | Audience paths | Implemented | Separate /us/hcp/ and /us/patients/ with a session-based HCP attestation gate for clinical resources. |
| 15 | 14 ad landing pages | Blocked by DM-0002 | Exact page list, headlines, campaign audience, and CTA mapping were not supplied. No invented ad-matching pages created. |
| 16 | Ordering pathway | Partial | Clinician checklist and state-check flow implemented. US requisition, kit workflow, specimen quantities, logistics, turnaround, and secure endpoint require operational approval. |
| 17 | Sample report | Partial | HTML report overview added. Existing 2022 examples found but not represented as current US-approved reports. |
| 18 | US contact | Pending details | General coordination email retained with no-health-information guidance. US phone, hours, named contact, and Raleigh service status unverified. |
| 19 | Patient materials | Implemented as review drafts | Discussion guide, downloadable English PDF, caregiver page, and after-ordering guide. Clinical/plain-language approval pending. |
| 20 | Evidence hub | Implemented as review drafts | Five HTML publication summaries with DOI, design, population, endpoints, results, limitations, funding, and conflicts. Clinical sign-off pending. |
| 21 | Structured data | Partial | Organization, MedicalWebPage, and visible FAQPage JSON-LD. No fabricated author Person or unverified Quantilli sameAs. |
| 22 | US English / hreflang | Partial | US English used. Spanish patient pages identify language. No en-gb/en-in alternate links invented; regional equivalents require mapping. |
| 23 | Clinical authorship | Pending reviewer | Editorial date and pending-review status shown; no one falsely credited with medical approval. |
| 24 | Tumor question pages | Blocked by DM-0001 | Twenty questions per tumor type and approved answers needed. |
| 25 | Payer objections | Implemented as review draft | HCP page covers evidence limitations, investigational classifications, and financial responsibility. |
| 26 | Performance | Partial | US template uses small local assets, system fonts, no embeds, and no tracking SDKs. Field Core Web Vitals cannot be certified from a UAT test. |
| 27 | Accessibility | Partial | Semantic headings, keyboard-accessible forms/gates, visible focus, skip link, responsive layout, no autoplay or motion requirement. Full WCAG audit, legacy PDFs, and PDF tagging remain. |
| 28 | Spanish | Partial | Spanish patient overview and printable discussion guide drafted. Qualified medical translation review and other patient-page translations remain. |
| 29 | Measurement | Pending approved architecture | No live GA4, ad tags, CRM writes, or gclid capture enabled on UAT. Consent/event plan provided in handoff. |
| 30 | Rename readiness | Pending brand confirmation | No now-Quantilli claim or redirects deployed without approved timing, entity URLs, and redirect map. |
Chrome review steps
- Open the US homepage on desktop and at 390px mobile width. Review headings, cards, menus, and footer.
- Open the clinician path in an Incognito window. Confirm content appears only after self-attestation. Close the session to clear the session cookie.
- Check New York and California: ordering must be unavailable. Check Texas: availability must require verification. No state should create an order.
- Open each study and its DOI. Review the patient guide and PDF; compare English and Spanish drafts.
- Open DevTools Network on US pages. Confirm no analytics, advertising, external fonts, maps, or other third-party requests load.
- Use only the keyboard to reach menus, links, checkboxes, buttons, and FAQ questions.
- Dismiss the essential-only notice, reload, and reset the preference from the privacy page.
Claude extension prompts
Use the prepared prompts for browser review and for remaining work once the required approved information is available.
Open the Claude extension prompts